Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Keywords: Medicine ; Cancer Research ; Immunology ; Oncology ; Cytokines ; Growth factors ; Cell Biology ; Biomedicine ; Immunology ; Cancer Research ; Cytokines and Growth Factors ; Oncology ; Cell Biology ; Springer eBooks
    Abstract: This book discusses the immunotherapeutic potential of Interleukin 12 in the context of clinical oncology, as well as antitumor effects confirmed in preclinical studies and clinical trials in cancer immunotherapy. Due to its ability to activate both innate (NK cells) and adaptive (cytotoxic T lymphocytes) immunities, Interleukin 12 (IL-12) has been regarded as a promising candidate for tumor immunotherapy. However, despite the encouraging results in animal models, only very modest antitumor effects have been confirmed in early clinical trials. Recently, several clinical studies have been initiated in which IL-12 was applied as an adjuvant in cancer vaccines, in gene therapy including locoregional injections of IL-12 plasmid, and in the form of tumor-targeting immunocytokines (IL-12 fused to monoclonal antibodies)
    Pages: VII, 75 p. 6 illus. : online resource.
    ISBN: 9783319469065
    Signatur Availability
    BibTip Others were also interested in ...
  • 2
    ISSN: 1432-0851
    Keywords: Tumor necrosis factor α ; Interferon γ ; Macrophage-colony-stimulating factor ; Tumor immunotherapy
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract The efficacy of systemic infusion of recombinant human macrophage-colony-stimulating factor (M-CSF) in combination with local treatment with human recombinant tumor necrosis factor (TNF) α and mouse recombinant interferon (IFN) γ was studied in vivo on a subclone of B16 melanoma (MmB16) in mice. Short-term intravenous administration of M-CSF at a dose of 106 units daily had no antitumor effect in vivo. Similarly, local treatment of tumor with TNFα (5 μg daily) did not produce any therapeutic effect. However, simultaneous administration of the same dose of TNFα with IFNγ (1000 units daily) resulted in a synergistic effects manifested by the retardation of tumor growth. Addition of systemic infusion of M-CSF to the local therapy with TNFα and IFNγ induced further augmentation of antitumor efficacy and delayed progression of MmB16 melanoma. The strengthened antitumor effect of combination therapy including M-CSF, TNFα and IFNγ was most probably due to the increased release of monocytes from the bone marrow, their recruitment into the site of tumor growth and subsequent local stimulation of their antitumor activity.
    Type of Medium: Electronic Resource
    Signatur Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...